Document Detail

Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema.
MedLine Citation:
PMID:  3470169     Owner:  NLM     Status:  MEDLINE    
We report the case of a patient with scleromyxedema with abnormal monoclonal gamma globulin of the kappa type who was treated with melphalan (Alkeran), an alkylating agent. After nine and one-half years of therapy, the patient showed myelomonocytic leukemia. The risk of secondary malignancies must be considered when weighting the benefits and risks of melphalan treatment.
F Helm; T N Helm
Related Documents :
21524949 - Small-incision orbicularis-levator fixation technique: a modified double-eyelid blephar...
19950129 - Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence s...
282809 - Leukemia in radiation-treated patients: cytogenetic studies in eight cases.
18061959 - A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 aml ...
10678699 - Large plaque parapsoriasis: clinical and genotypic correlations.
20633929 - Improvement of the who classification-based prognostic scoring system (wpss) by includi...
12561149 - Causes of early post carotid endartectomy stroke in a recent series: the increasing imp...
23998759 - Ventricular cycle length characteristics estimative of prolonged rr interval during atr...
19685419 - The patient with asymptomatic shortened cervix at 23 to 28 weeks: is delivery imminent?
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Cutis     Volume:  39     ISSN:  0011-4162     ISO Abbreviation:  Cutis     Publication Date:  1987 Mar 
Date Detail:
Created Date:  1987-05-12     Completed Date:  1987-05-12     Revised Date:  2013-09-12    
Medline Journal Info:
Nlm Unique ID:  0006440     Medline TA:  Cutis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  219-23     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Diabetes Mellitus, Type 1 / complications
Leukemia, Myeloid / chemically induced*
Melphalan / adverse effects*
Paraproteinemias / blood,  complications*
Scleroderma, Systemic / complications,  drug therapy,  physiopathology*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Elimination of enoxacin in renal disease.
Next Document:  Selective repression of RNA polymerase II by microinjected phosvitin.